An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain

Manuel L. Penichet, Young Sook Kang, William M. Pardridge, Sherie L. Morrison, Seung-Uon Shin

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

In the present study a novel Ab-avidin fusion protein has been constructed to deliver biotinylated compounds across the blood brain barrier. This fusion molecule consists of an Ab specific for the transferrin receptor genetically fused to avidin. The Ab-avidin fusion protein (anti-TfR IgG3- C(H)3-Av) expressed in murine myeloma cells was correctly assembled and secreted and showed both Ab- and avidin-related activities. In animal models, it showed much longer serum half-life than the chemical conjugate between OX- 26 and avidin. Most importantly, this fusion protein demonstrated superior [3H]biotin uptake into brain parenchyma in comparison with the chemical conjugate. We also delivered a biotinylated 18-mer antisense peptide-nucleic acid specific for the rev gene of HIV-1 to the brain. Brain uptake of the HIV antisense drug was increased at least 15-fold when it was bound to the anti- TfR IgG3-C(H)3-Av, suggesting its potential use in neurologic AIDS. This novel Ab fusion protein should have general utility as a universal vehicle to effectively deliver biotinylated compounds across the blood-brain barrier for diagnosis and/or therapy of a broad range of CNS disorders such as infectious diseases, brain tumors as well as Parkinson's and Huntington's diseases.

Original languageEnglish
Pages (from-to)4421-4426
Number of pages6
JournalJournal of Immunology
Volume163
Issue number8
StatePublished - Oct 20 1999
Externally publishedYes

Fingerprint

Anti-HIV Agents
Transferrin Receptors
Avidin
Antibodies
Brain
Proteins
Blood-Brain Barrier
rev Genes
Immunoglobulin G
Peptide Nucleic Acids
Huntington Disease
Biotin
Brain Neoplasms
Nervous System
Communicable Diseases
Parkinson Disease
Half-Life
HIV-1
Acquired Immunodeficiency Syndrome
Animal Models

ASJC Scopus subject areas

  • Immunology

Cite this

An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting : Initial applications in anti-HIV antisense drug delivery to the brain. / Penichet, Manuel L.; Kang, Young Sook; Pardridge, William M.; Morrison, Sherie L.; Shin, Seung-Uon.

In: Journal of Immunology, Vol. 163, No. 8, 20.10.1999, p. 4421-4426.

Research output: Contribution to journalArticle

@article{d750b802ff6d42faa8b0fe6b3af741e8,
title = "An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain",
abstract = "In the present study a novel Ab-avidin fusion protein has been constructed to deliver biotinylated compounds across the blood brain barrier. This fusion molecule consists of an Ab specific for the transferrin receptor genetically fused to avidin. The Ab-avidin fusion protein (anti-TfR IgG3- C(H)3-Av) expressed in murine myeloma cells was correctly assembled and secreted and showed both Ab- and avidin-related activities. In animal models, it showed much longer serum half-life than the chemical conjugate between OX- 26 and avidin. Most importantly, this fusion protein demonstrated superior [3H]biotin uptake into brain parenchyma in comparison with the chemical conjugate. We also delivered a biotinylated 18-mer antisense peptide-nucleic acid specific for the rev gene of HIV-1 to the brain. Brain uptake of the HIV antisense drug was increased at least 15-fold when it was bound to the anti- TfR IgG3-C(H)3-Av, suggesting its potential use in neurologic AIDS. This novel Ab fusion protein should have general utility as a universal vehicle to effectively deliver biotinylated compounds across the blood-brain barrier for diagnosis and/or therapy of a broad range of CNS disorders such as infectious diseases, brain tumors as well as Parkinson's and Huntington's diseases.",
author = "Penichet, {Manuel L.} and Kang, {Young Sook} and Pardridge, {William M.} and Morrison, {Sherie L.} and Seung-Uon Shin",
year = "1999",
month = "10",
day = "20",
language = "English",
volume = "163",
pages = "4421--4426",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting

T2 - Initial applications in anti-HIV antisense drug delivery to the brain

AU - Penichet, Manuel L.

AU - Kang, Young Sook

AU - Pardridge, William M.

AU - Morrison, Sherie L.

AU - Shin, Seung-Uon

PY - 1999/10/20

Y1 - 1999/10/20

N2 - In the present study a novel Ab-avidin fusion protein has been constructed to deliver biotinylated compounds across the blood brain barrier. This fusion molecule consists of an Ab specific for the transferrin receptor genetically fused to avidin. The Ab-avidin fusion protein (anti-TfR IgG3- C(H)3-Av) expressed in murine myeloma cells was correctly assembled and secreted and showed both Ab- and avidin-related activities. In animal models, it showed much longer serum half-life than the chemical conjugate between OX- 26 and avidin. Most importantly, this fusion protein demonstrated superior [3H]biotin uptake into brain parenchyma in comparison with the chemical conjugate. We also delivered a biotinylated 18-mer antisense peptide-nucleic acid specific for the rev gene of HIV-1 to the brain. Brain uptake of the HIV antisense drug was increased at least 15-fold when it was bound to the anti- TfR IgG3-C(H)3-Av, suggesting its potential use in neurologic AIDS. This novel Ab fusion protein should have general utility as a universal vehicle to effectively deliver biotinylated compounds across the blood-brain barrier for diagnosis and/or therapy of a broad range of CNS disorders such as infectious diseases, brain tumors as well as Parkinson's and Huntington's diseases.

AB - In the present study a novel Ab-avidin fusion protein has been constructed to deliver biotinylated compounds across the blood brain barrier. This fusion molecule consists of an Ab specific for the transferrin receptor genetically fused to avidin. The Ab-avidin fusion protein (anti-TfR IgG3- C(H)3-Av) expressed in murine myeloma cells was correctly assembled and secreted and showed both Ab- and avidin-related activities. In animal models, it showed much longer serum half-life than the chemical conjugate between OX- 26 and avidin. Most importantly, this fusion protein demonstrated superior [3H]biotin uptake into brain parenchyma in comparison with the chemical conjugate. We also delivered a biotinylated 18-mer antisense peptide-nucleic acid specific for the rev gene of HIV-1 to the brain. Brain uptake of the HIV antisense drug was increased at least 15-fold when it was bound to the anti- TfR IgG3-C(H)3-Av, suggesting its potential use in neurologic AIDS. This novel Ab fusion protein should have general utility as a universal vehicle to effectively deliver biotinylated compounds across the blood-brain barrier for diagnosis and/or therapy of a broad range of CNS disorders such as infectious diseases, brain tumors as well as Parkinson's and Huntington's diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032825682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032825682&partnerID=8YFLogxK

M3 - Article

C2 - 10510383

AN - SCOPUS:0032825682

VL - 163

SP - 4421

EP - 4426

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -